Q1 2024 13F Holders as of 3/31/2024
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
46.7M
-
Number of holders
-
147
-
Total 13F shares, excl. options
-
56.2M
-
Shares change
-
+13.8M
-
Total reported value, excl. options
-
$1.79B
-
Value change
-
+$449M
-
Put/Call ratio
-
0.51
-
Number of buys
-
100
-
Number of sells
-
-52
-
Price
-
$31.86
Significant Holders of 4D Molecular Therapeutics, Inc. - Common Stock, par value $0.0001 per share (FDMT) as of Q1 2024
173 filings reported holding FDMT - 4D Molecular Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q1 2024.
4D Molecular Therapeutics, Inc. - Common Stock, par value $0.0001 per share (FDMT) has 147 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 56.2M shares
.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (5.05M shares), VR Adviser, LLC (4.4M shares), BlackRock Inc. (4.28M shares), BVF INC/IL (3.92M shares), JANUS HENDERSON GROUP PLC (3.2M shares), GOLDMAN SACHS GROUP INC (3.06M shares), Deep Track Capital, LP (3.03M shares), VIKING GLOBAL INVESTORS LP (2.93M shares), VANGUARD GROUP INC (2.34M shares), and STATE STREET CORP (2.18M shares).
This table shows the top 147 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.